BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel

BD Life Sciences, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced the availability of the U.S. Food and Drug Administration (FDA) cleared BD MAX™ Enteric Parasite Panel for use on the BD MAX System.

The BD MAX Enteric Parasite Panel is the latest panel in the BD MAX Enteric suite of assays that aid in the diagnosis of infectious gastroenteritis. This panel joins the BD MAX Enteric Bacterial Panel detecting the pathogens that are responsible for up to 95 percent of the bacteria causing gastroenteritis. With the availability of the BD MAX Enteric Parasite Panel, the majority of pathogens causing this disease can be detected with a fully automated, rapid and accurate platform.

The BD MAX Enteric Parasite Panel is a qualitative IVD test detecting DNA from Giardia lamblia, Cryptosporidium (C. hominis and C. parvum) and Entamoeba histolytica in both unpreserved and 10 percent formalin-fixed stool specimens.

"What we see as the value it will bring to us is the speed with which we can accurately provide patient results," said Kate Buehler, molecular specialist at Aspirus Wausau Hospital Reference Laboratory. "Coupled with the BD MAX Enteric Bacterial panel, it allows us to provide a flexible diagnostic solution with ease."

Doug White, vice president and general manager, Molecular Diagnostics & Women's Health, BD Life Sciences said, "We continue to expand the BD MAX System menu of unique, clinically relevant panels. BD's suite of enteric assays will allow flexibility for specific testing needs based on patient and clinical presentation, enabling more efficient patient management and laboratory processes."

Globally, there are approximately 1.7 billion cases of diarrhea accounting for more than 2 million deaths annually. Children less than 5 years of age are particularly at risk with around 760,000 deaths each year. These infections may be caused by viruses, bacteria or parasites and often take two to three days or more to identify in the clinical laboratory using conventional methods. Infections caused by the parasites Giardia and Cryptosporidia, while relatively common, may be subject to under-diagnosis and reporting in the US.

"The BD MAX assays for Clostridium difficile (C. diff) and selected enteric bacterial and parasitic pathogens are the first commercial assays for selective, targeted diagnosis of enteric infectious diseases, an approach that is consistent with the recommendations of the American Society of Microbiology and the Infectious Disease Society of America," said Patrick Murray, Ph.D., senior director of Worldwide Scientific Affairs, BD Diagnostics.

In the laboratory, the BD MAX System automates sample preparation, extraction, amplification and detection on a single system, saving time and improving lab efficiency. Molecular testing on the BD MAX System is simplified and standardized, to minimize variability in results.

"The BD MAX Enteric Parasite Panel addition to the menu will further streamline our workflow, improve turnaround time and free up staff that were previously running EIA testing manually," said Annette Monterrubio, Microbiology & Molecular Biology System technical coordinator at St. Luke's Health System, Boise, Idaho. "I believe this will greatly benefit patient care."

The BD MAX menu includes syndromic panels for Healthcare Associated Infections, Reproductive & Sexually Transmitted Infections and Enteric Pathogens, enabling lab professionals in their efforts to deliver diagnostic results that improve lab operations.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BD (Becton, Dickinson and Company). (2019, June 19). BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel. News-Medical. Retrieved on June 20, 2024 from https://www.news-medical.net/news/20150924/BD-Life-Sciences-announces-FDA-clearance-for-BD-MAX-Enteric-Parasite-Panel.aspx.

  • MLA

    BD (Becton, Dickinson and Company). "BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel". News-Medical. 20 June 2024. <https://www.news-medical.net/news/20150924/BD-Life-Sciences-announces-FDA-clearance-for-BD-MAX-Enteric-Parasite-Panel.aspx>.

  • Chicago

    BD (Becton, Dickinson and Company). "BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel". News-Medical. https://www.news-medical.net/news/20150924/BD-Life-Sciences-announces-FDA-clearance-for-BD-MAX-Enteric-Parasite-Panel.aspx. (accessed June 20, 2024).

  • Harvard

    BD (Becton, Dickinson and Company). 2019. BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel. News-Medical, viewed 20 June 2024, https://www.news-medical.net/news/20150924/BD-Life-Sciences-announces-FDA-clearance-for-BD-MAX-Enteric-Parasite-Panel.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
BD launches new safety blood collection device in the UK